Role of Traditional Heart Failure Medications on Sudden Cardiac Death Prevention in Patients with Cardiomyopathy

摘要: Sudden cardiac death (SCD) remains a major public health issue with an estimated annual inci‐ dence of 300,000 cases per year. The ACC/AHA/ESC 2006 guidelines define SCD as “death from unexpected circulatory arrest, usually due to arrhythmia occurring within hour the onset symptoms” [1]. Trials on traditional antiarrhythmic drugs have failed show any mortality benefit even when compared placebo or implantable cardiovertor defibrilla‐ tors (ICDs) [2]. Most patients experiencing sudden arrest left ventricular ejection fraction (LVEF) > 50%, majority these having history coronary artery disease (CAD). Majority Cardiac Arrests (85-90%) are first arrhythmic event patient experiences[3].Beta blocker therapy, Angiotensin enzymes inhibitors (ACE-I) well aldosterone antagonists been shown decrease risk especially in post myocardial infarction (MI) and congestive heart fail‐ ure. This chapter will review data effects failure medications, es‐ pecially beta blockers, Renin system Statin therapy MI cardiomyopathy.